Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by Integral Health Asset Management LLC

Integral Health Asset Management LLC boosted its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 36.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 375,000 shares of the company's stock after buying an additional 100,000 shares during the quarter. Scholar Rock accounts for about 1.4% of Integral Health Asset Management LLC's holdings, making the stock its 25th biggest holding. Integral Health Asset Management LLC owned approximately 0.40% of Scholar Rock worth $16,208,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC lifted its stake in Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after acquiring an additional 269 shares during the last quarter. Global Retirement Partners LLC lifted its stake in Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after acquiring an additional 766 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in Scholar Rock by 1,321.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after purchasing an additional 1,031 shares in the last quarter. Amalgamated Bank raised its holdings in Scholar Rock by 30.6% during the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company's stock worth $114,000 after purchasing an additional 620 shares in the last quarter. Finally, KBC Group NV acquired a new stake in Scholar Rock during the fourth quarter worth approximately $131,000. Hedge funds and other institutional investors own 91.08% of the company's stock.

Scholar Rock Stock Down 0.2%

Shares of Scholar Rock stock traded down $0.07 on Friday, hitting $30.76. 490,958 shares of the company's stock traded hands, compared to its average volume of 1,270,240. The stock has a market cap of $2.92 billion, a P/E ratio of -13.09 and a beta of 0.37. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The firm's 50-day moving average is $31.26 and its 200 day moving average is $35.87. Scholar Rock Holding Co. has a 52-week low of $6.76 and a 52-week high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). Equities analysts anticipate that Scholar Rock Holding Co. will post -2.42 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Wedbush reissued an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a research note on Wednesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Scholar Rock has an average rating of "Buy" and a consensus price target of $42.67.

Insider Buying and Selling

In other Scholar Rock news, CEO Jay T. Backstrom sold 18,372 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total value of $676,640.76. Following the sale, the chief executive officer now directly owns 311,991 shares in the company, valued at approximately $11,490,628.53. This trade represents a 5.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Edward H. Myles sold 7,809 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $36.83, for a total value of $287,605.47. Following the completion of the sale, the chief financial officer now owns 140,740 shares in the company, valued at $5,183,454.20. The trade was a 5.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 255,231 shares of company stock worth $9,220,236 over the last ninety days. 13.30% of the stock is owned by insiders.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.